US stock · Healthcare sector · Medical Devices
Company Logo

Glaukos Corporation

GKOSNYSE

39.34

USD
+0.31
(+0.79%)
Market Closed
-66.71P/E
-30Forward P/E
-2.57P/E to S&P500
1.862BMarket CAP
- -Div Yield

Glaukos Corporation

NYSE:GKOS

RECENT
PRICE

39.34

P/E
RATIO

-66.71

(PEG:-1.10)

P/E RATIO
RELATIVE
TO S&P

-2.57

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.48 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

- -

- -

- -

- -

- -

- -

- -

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

0.84

(0.51)

(0.57)

- -

1.91

(0.51)

(0.33)

- -

4.10

(2.13)

(0.18)

- -

3.47

0.14

0.18

- -

4.63

(0.00)

0.56

- -

5.13

(0.37)

0.24

- -

6.34

0.41

(0.14)

- -

5.06

(2.70)

(0.67)

- -

6.29

(1.06)

(0.49)

- -

6.29

(0.61)

(0.15)

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

0.03

0.60

0.04

0.25

0.05

5.45

0.19

3.56

0.18

4.02

0.29

4.92

0.13

18.02

0.16

15.00

1.02

12.56

0.80

12.68

CAPEX per share

Book Value per share

- -

- -

- -

- -

- -

- -

- -

25

24

17

33

34

35

37

44

47

47

Comm.Shares outs.(m)

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

(12.6)

(0.6)

- -

193.5

8.7

- -

(14,440.0)

(612.1)

- -

(122.1)

(4.9)

- -

164.3

6.8

- -

(17.9)

(0.5)

- -

(65.0)

(2.2)

- -

(66.7)

(2.6)

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$455 m.

Total assets
$1,052 m.

Long-term debt
$382 m.

Cash and equiv.
$106 m.

Goodwill $66 m.

Retained earnings $(360) m.

Common stock 47 m. shares

Market Capitalisation
$1,862 m. (as of 21/5/22)

- -

- -

- -

- -

21

(67.8)%

46

(28.9)%

72

(14.4)%

114

3.7%

159

(1.4)%

181

(7.2)%

237

(21.2)%

225

(54.9)%

294

(11.2)%

294

(3.3)%

Revenue (m)

Operating margin

- -

- -

- -

- -

1

(13)

4

(12)

4

(37)

5

5

5

(0)

6

(13)

10

15

35

(120)

34

(50)

33

(28)

Depreciation (m)

Net profit (m)

- -

- -

- -

- -

(0.0)%

(60.3)%

(0.1)%

(26.6)%

(0.1)%

(51.9)%

0.9%

4.0%

9,300.0%

(0.1)%

(4.7)%

(7.1)%

130.8%

6.5%

9.0%

(53.5)%

(0.7)%

(16.9)%

2.3%

(9.0)%

Income tax rate

Net profit margin

- -

- -

- -

- -

- -

- -

6

18

15

(10)

9

6

84

1

95

103

- -

117

123

- -

138

146

- -

174

205

73

673

420

271

667

423

382

587

436

382

598

Working capital (m)

Long-term debt (m)

Equity (m)

- -

- -

- -

- -

- -

- -

(37.2)%

(31.9)%

(84.8)%

(72.8)%

(31.5)%

(199.4)%

(37.6)%

(31.0)%

(39.1)%

4.4%

3.8%

3.9%

(3.0)%

0.0%

(0.1)%

(7.3)%

(6.0)%

(7.4)%

1.9%

(5.8)%

2.3%

(11.2)%

(11.8)%

(18.0)%

(3.7)%

(3.4)%

(8.4)%

(1.4)%

(1.3)%

(4.6)%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

174

208

212

Receivables

38

36

33

Inventory

43

16

23

Other

8

13

16

Current assets

263

469

486

Acc. Payable

6

4

7

Debt due

- -

- -

- -

Other

52

45

56

Current liab.

58

50

63

- -

- -

- -

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

Glaukos Corporation (US) started trading on June 4, 2015 (cik: 0001192448), operates in the Healthcare sector (Medical Devices industry), has 727 full-time employees, and is led by Mr. Thomas Burns. Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

17.55%

- -

Cash flow

62.40%

- -

Earnings

3204.76%

- -

Dividends

- -

- -

Book value

75.04%

- -

Insider trading

Type

Shares

Date

Kliman Gilbert H

Other

980

05/18/22

Kliman Gilbert H

Other

980

05/18/22

Navratil Tomas

InKind

338

04/19/22

Gilliam Joseph E

InKind

672

04/19/22

Burns Thomas William

InKind

3,823

04/19/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

55

32

65

73

225

2021

68

78

75

73

294

2022

68

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

(1.21)

(0.90)

(0.35)

(0.24)

-2.70

2021

(0.35)

(0.37)

0.13

(0.47)

-1.06

2022

0.11

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -